Cyclin-dependent kinase 4/6 inhibitors, known as CDK4/6 inhibitors, work by blocking two enzymes that drive the cell division cycle. In hormone receptor-positive breast cancer, tumor cells rely heavily on signaling through cyclin D and the kinases CDK4 and CDK6 to proliferate, and pairing one of these inhibitors with endocrine therapy such as an aromatase inhibitor or fulvestrant has been shown in landmark phase III trials—including PALOMA, MONALEESA, MONARCH, and DAWNA—to dramatically extend the time patients live without their disease progressing. Yet pivotal clinical trials enroll carefully selected patients under tightly controlled conditions, and the outcomes of ordinary patients in routine clinical practice, who are often older, have more comorbidities, or fall outside trial eligibility criteria, can differ substantially. That gap between trial efficacy and real-world effectiveness is precisely what the new study was designed to address.

The retrospective multicenter analysis drew on records from patients treated at 20 cancer centers across central China, making it one of the most geographically diverse real-world datasets of its kind. CDK4/6 inhibitors were used as first-line therapy in 65.68 percent of the cohort and as second-line treatment in 24.60 percent, with the remainder receiving the drugs later in their treatment course. The primary endpoint was progression-free survival, the length of time a patient lives without evidence of tumor growth or spread, assessed using imaging criteria and Kaplan–Meier statistical methods. The findings confirmed a striking advantage for earlier use: median progression-free survival reached 38.0 months in patients who received a CDK4/6 inhibitor as their first systemic treatment for metastatic disease, compared with 18.8 months among those who began the drugs only after prior lines of therapy had failed, a difference that was highly statistically significant with a P value below 0.001. In other words, patients who received the drugs first lived roughly twice as long without progression.

Beyond treatment timing, the investigators used multivariable Cox regression analysis to identify which patient characteristics independently shaped prognosis. Cox regression is a statistical technique that estimates the effect of multiple variables simultaneously on the risk of an event such as disease progression, while accounting for the fact that not all patients have been followed for the same length of time. Three factors emerged as adverse prognostic markers: having the Luminal B molecular subtype of breast cancer, which tends to be more aggressive than Luminal A disease; the presence of liver metastases, a known indicator of higher disease burden; and receiving the CDK4/6 inhibitor as second-line rather than first-line treatment. Conversely, two features were associated with better outcomes: tumors with HER2 immunohistochemistry score of 1+, a faint level of HER2 protein expression sometimes called HER2-low, and a longer disease-free interval between the initial diagnosis and the development of metastatic disease. Each of these findings aligns with, and extends, signals from smaller studies conducted in Europe, Japan, and North America.

To translate these population-level findings into a tool usable at the bedside, the team split patients receiving first- or second-line CDK4/6 inhibitors into a training cohort and a validation cohort in a seven-to-three ratio. On the training data they built a conventional Cox regression model and seven distinct machine learning algorithms designed for survival data: gradient boosting machines (GBM), random survival forests (RSF), Lasso-Cox, CoxBoost, XGBoost, super principal component analysis (SuperPC), and partial least squares regression for Cox data (plsRcox). These methods differ in how they handle complexity. Random survival forests, for example, grow many decision trees on bootstrap samples of the data and average them to capture non-linear relationships, while gradient boosting builds an ensemble of weak learners sequentially, each correcting the errors of the last. Lasso-Cox applies a penalty that shrinks coefficients and performs variable selection automatically, guarding against overfitting in datasets with many correlated predictors.

Model performance was evaluated using three complementary approaches: time-dependent area under the receiver operating characteristic curve (AUC), which measures discrimination, meaning the ability to correctly rank patients who progress sooner above those who progress later; calibration plots, which test whether predicted probabilities match observed outcomes; and decision curve analysis, which quantifies the clinical net benefit of acting on the model’s predictions at various risk thresholds. The conventional Cox model achieved respectable discrimination, with AUCs of 0.731, 0.719, and 0.704, values that indicate clinically meaningful predictive accuracy without reaching the level of certainty that would justify replacing clinician judgment. Among the machine learning approaches, gradient boosting machines and random survival forests showed the highest discrimination in the training cohort but settled into only moderate performance when tested on the held-out validation cohort, a pattern that reflects the classic challenge of overfitting, in which flexible algorithms memorize quirks of the training data that do not generalize to new patients.

The comparison between the Cox model and the machine learning alternatives carries a broader lesson for the field of computational oncology. Machine learning methods are often assumed to outperform classical regression simply because they are more sophisticated, but the evidence from survival prediction research is mixed, and recent systematic reviews have found that the two approaches frequently perform comparably when applied to modest-sized clinical datasets. The authors of the new study conclude that both the Cox model and the machine learning frameworks enable individualized prognostic prediction for CDK4/6 inhibitor therapy, but they emphasize that the GBM and RSF models performed relatively better and that external validation in independent patient populations remains essential before any of the tools can be deployed in routine clinical practice. This cautious stance mirrors the standards set by the TRIPOD reporting guidelines, which require transparent documentation of prediction model development and validation.

The study’s real-world effectiveness data carry important implications for treatment sequencing guidelines. Because median progression-free survival was double in the first-line setting, the findings reinforce the strategy of deploying CDK4/6 inhibitors upfront in combination with endocrine therapy rather than reserving them for later lines, consistent with the design of trials such as PALOMA-2, MONALEESA-2, MONARCH 3, and DAWNA-2. The finding that HER2-low tumors fared better adds to a growing body of evidence that the HER2-low subgroup, which was historically lumped together with HER2-zero disease, may represent a biologically and clinically distinct entity, with consequences for eligibility for novel antibody-drug conjugates as well. Meanwhile, the adverse prognostic weight of liver metastases and Luminal B biology provides clinicians with concrete variables to weigh when counseling patients and planning surveillance intensity.

The research also has significance for Chinese and other Asian patient populations, where locally relevant real-world evidence has historically been thinner than in Western Europe and North America. The cohort included patients treated with agents available in China, and the treatment patterns observed—first-line use in roughly two-thirds of patients—suggest substantial but incomplete uptake of guideline-concordant sequencing. The study protocol was registered at ClinicalTrials.gov, conducted under the Declaration of Helsinki, and approved by the Ethics Committee of Hunan Cancer Hospital, which waived the requirement for individual written informed consent given the retrospective, anonymized nature of the data. Funding came from the Hunan Provincial Natural Science Foundation, Hunan Cancer Hospital programs, and two Chinese medical foundations, and the authors declared no competing interests.

For patients with hormone receptor-positive, HER2-negative metastatic breast cancer, the most immediate message is one of cautious optimism: in the messy reality of everyday oncology, CDK4/6 inhibitors deliver substantial benefit, with first-line patients in this large cohort living a median of more than three years without progression. For the oncology community, the study demonstrates a rigorous template for building prognostic tools from real-world data, combining the interpretability of classical survival regression with the flexibility of modern machine learning. And for the rapidly expanding field of AI-assisted medicine, it serves as a measured reminder that predictive power must be validated, calibrated, and externally confirmed before an algorithm earns a place in the clinic. As external validation cohorts are assembled, the models described in this work may eventually help oncologists answer one of the most practical questions in metastatic breast cancer care: which patient, with which tumor, is likely to benefit most, and for how long, from these transformative drugs.

Colorectal cancer stands as the third most common cancer globally and disproportionately affects individuals over the age of 50. Despite its prevalence, the precise etiology of colorectal cancer remains obscure, with only a handful of known risk factors identified. Current treatment modalities include surgery, chemotherapy, radiotherapy, and targeted biological therapies, but the emergence of resistance to these treatments frequently leads to disease progression and relapse. Addressing this challenge demands novel insights into cancer cell biology and the mechanisms underlying therapeutic resistance.

Published in the prestigious journal Oncogene, this preclinical study sheds light on a metabolic mechanism at the heart of colorectal cancer cells’ resistance to palbociclib, a cyclin-dependent kinase inhibitor (CDKI) that has notably expanded its therapeutic reach beyond breast cancer. Palbociclib targets CDK4 and CDK6—enzymes integral to cell cycle regulation and proliferation—effectively halting the uncontrolled growth of malignant cells. However, the cancer cells’ ability to reprogram their metabolism undermines its efficacy, enabling cell survival despite treatment.

Led by Professor Marta Cascante and Dr. Timothy M. Thomson, the research team utilized a multidimensional approach incorporating metabolomics, fluxomics, and systems biology to dissect how colorectal cancer cells adapt under the pressure of palbociclib. Their focus centered on glutaminase, an enzyme that catalyzes the conversion of glutamine to glutamate, critical for sustaining cancer cell bioenergetics and biosynthesis. Previous findings indicated increased glutaminase activity as a resistance factor, yet the integrative impact of targeting this metabolic vulnerability in combination with CDK4/6 inhibition had remained unexplored until now.

The team meticulously examined the metabolic reprogramming that occurs after palbociclib treatment. Surviving colorectal cancer cells exhibited enhanced glutamine metabolism and mitochondrial activity, reflecting a strategic shift to meet the heightened energetic and anabolic demands required for continued survival and proliferation. Such adaptive rewiring enables these cells to bypass the blockade imposed by CDK4/6 inhibition, effectively rendering monotherapy insufficient.

To counter this, telaglenastat—a highly selective glutaminase inhibitor—was introduced alongside palbociclib. By disrupting glutamine catabolism, telaglenastat thwarts the metabolic compensation that cancer cells rely upon following CDK4/6 inhibition. This dual targeting strategy produced a potent synergistic effect, dramatically impeding tumor cell growth both in cell cultures and in vivo animal models. The findings illustrate that the two drugs complement each other by mitigating each other’s metabolic escape routes, thereby trapping cancer cells in a metabolic bottleneck they cannot escape.

This synergy offers several advantages, not least of which is the potential to delay or entirely prevent the onset of drug resistance, a major clinical hurdle. The research underscores the intricate interplay between cell cycle regulation and metabolic pathways in cancer and highlights the importance of integrated therapeutic designs that transcend singular molecular targets. By simultaneously facing down oncogenic proliferation and metabolic adaptability, this combination therapy could redefine treatment paradigms for colorectal cancer.

Moreover, these insights open avenues for personalized medicine approaches whereby metabolic profiling of tumors could guide tailored treatment regimens. Recognizing that metabolic plasticity is a hallmark of cancer progression, the ability to predict and counteract resistance mechanisms at the metabolic level promises enhanced precision and efficacy. This approach aligns with emerging trends emphasizing the metabolic dependencies of cancer cells as critical therapeutic targets.

The study’s preclinical evidence lays a strong foundation for upcoming clinical trials to evaluate the safety, optimal dosing, and therapeutic benefits of palbociclib and telaglenastat in combination. While the journey from bench to bedside remains complex, the robust data presented provide compelling justification for fast-tracking this combination into clinical testing phases. Success in this domain could translate into improved survival rates and quality of life for patients battling colorectal cancer.

Beyond its immediate clinical implications, the research advances our fundamental understanding of cancer cell metabolism and resistance biology. It exemplifies the necessity of systems biology approaches in unraveling the multilayered networks cancer cells exploit and paves the way for future discoveries that may extend to other malignancies exhibiting similar resistance profiles.

The work is a testament to international scientific collaboration, involving researchers from the University of Barcelona, the Molecular Biology Institute of Barcelona, the Francis Crick Institute in the UK, and other entities specializing in bioinformatics and systems medicine. This collective expertise was instrumental in integrating cutting-edge experimental techniques with computational analysis to reveal actionable therapeutic strategies.

In sum, this research heralds a novel, metabolically informed combat strategy against colorectal cancer’s notoriously adaptive nature. By targeting the dual pillars of cell division and metabolic reprogramming, the palbociclib and telaglenastat combination stands poised to slash through the barriers of drug resistance and chart new territory in cancer therapy. The anticipation surrounding forthcoming clinical applications is high, generating hope for millions worldwide affected by this devastating disease.

Subject of Research: Animals
Article Title: Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells
News Publication Date: 22-Jul-2025
Web References: https://www.nature.com/articles/s41388-025-03495-w
References: DOI: 10.1038/s41388-025-03495-w
Image Credits: UNIVERSITY OF BARCELONA
Keywords: Pharmacology

The team focused on the consequences of DNA2 depletion in human RPE-1 cells by using an inducible degron system combined with DIA treatment to induce rapid DNA2 degradation. This model allowed the researchers to monitor cellular responses to acute DNA2 loss without introducing exogenous DNA damage. Intriguingly, they found that cells deficient in DNA2 activate ATR-dependent checkpoint signaling, which culminates in phosphorylation of CHK1, a key effector in the DNA damage response pathway, even in the absence of external genotoxic stress.

This CHK1 phosphorylation peaks around 12 hours after DNA2 is depleted, preceding the gradual degradation of the CHK1 protein itself—a hallmark of cells exiting from the G2 phase of the cell cycle. Concomitantly, levels of the cyclin-dependent kinase inhibitor p21 rise significantly and persist, suggesting an irreversible commitment to cell-cycle withdrawal. The accumulation of p21 plays a pivotal role by sequestering cyclin B1 within the nucleus and promoting its degradation, effectively preventing mitotic entry and pushing cells toward senescence.

Further observations revealed a compelling relocalization of cyclin B1 from the cytoplasm to the nucleus in DNA2-depleted cells, preceding nuclear enlargement, a quintessential marker of cellular senescence. By tracking β-galactosidase activity, a classical senescence biomarker, the researchers confirmed that these cells adopt a senescent phenotype over a 14-day period following DNA2 loss. This phenotype mirrors the effects of pharmacological induction of senescence, reinforcing the link between DNA2 function and cell fate decisions post-replication stress.

Notably, ATR inhibition or siRNA-mediated knockdown of p21 alleviated this senescent arrest, allowing cells to bypass the mitotic block instituted by DNA2 deficiency. However, this escape was achieved at a cost: the appearance of micronuclei, indicative of genomic instability stemming from incomplete or defective chromosomal replication. This finding highlights the critical checkpoint function DNA2 exerts in ensuring that replication intermediates are adequately resolved before cell division occurs.

Examining replication protein A (RPA) foci, the researchers observed that DNA2 loss triggers RAD51-dependent accumulation of RPA bound to single-stranded DNA (ssDNA) in G2 phase cells. This accumulation coincided with the nuclear translocation and eventual disappearance of cyclin B1, underscoring a mechanistic link between stalled replication intermediates and checkpoint-enforced cell-cycle exit. Surprisingly, DNA double-strand break-specific phosphorylation of RPA32 was infrequent, suggesting that the replication stress induced by DNA2 depletion involves stalled, unbroken replication forks rather than extensive DNA breakage.

Mechanistically, DNA2 appears to act at stalled replication forks by processing DNA intermediates, counteracting fork reversal and promoting fork reactivation. The loss of DNA2 leads to persistent reversed forks, which give rise to a phenomenon termed homologous recombination restarted replication (HoRReR). HoRReR involves unscheduled recombination-dependent DNA synthesis that generates ssDNA, thereby triggering ATR checkpoint activation and enforcing G2 arrest.

Complementation experiments utilizing mutant DNA2 variants revealed that both the nuclease and helicase activities are indispensable for suppressing the deleterious phenotypes observed upon DNA2 loss. Only the expression of wild-type DNA2 could restore replication fork stability and prevent aberrant checkpoint activation, demonstrating the coordinated enzymatic functions necessary for maintaining replication fidelity.

These insights significantly refine our understanding of DNA2’s essentiality for cell proliferation by connecting its enzymatic role at replication forks to a broader cellular response that safeguards genome stability. The inability to properly process reversed replication forks initiates a cascade of events: excessive recombination-based DNA synthesis, ssDNA accumulation, ATR-dependent checkpoint signaling, p21-mediated cyclin B1 sequestration, and ultimately, permanent cell-cycle exit.

This work expands the paradigm of replication stress responses by identifying DNA2 as a crucial gatekeeper that restricts aberrant recombination-restarted replication and enforces cell-cycle withdrawal before mitosis. It underscores the fine balance cells must strike between repair and proliferation and highlights DNA2 as a potential therapeutic target in diseases characterized by dysregulated replication stress responses, such as cancer.

Moreover, the findings suggest that therapeutic modulation of DNA2 activity might sensitize cells to replication stress or promote senescence in rapidly dividing tumor cells. Conversely, inhibition of downstream effectors such as p21 may allow cells to override replication stress-induced checkpoints, albeit at the risk of increased genomic instability—a double-edged sword in cancer therapy.

Future investigations will likely explore how DNA2 interfaces with other replisome components and DNA repair factors to orchestrate replication fork dynamics. Understanding the interplay between DNA2 and the ATR–CHK1–p21 axis may unveil novel strategies for manipulating checkpoint responses and controlling cell proliferation under replicative stress conditions.

Ultimately, this study shines a spotlight on the intricate molecular choreography required to preserve genome integrity during DNA replication. DNA2’s role transcends mere enzymatic activity; it enforces a cellular checkpoint that prevents catastrophic chromosomal missegregation, thereby ensuring faithful cell division and organismal homeostasis.

Subject of Research:
Role of DNA2 in replication fork processing, ATR checkpoint activation, and cell-cycle exit mechanisms in human cells.

Article Title:
DNA2 enables growth by restricting recombination-restarted replication.

Article References:
Hudson, J.J.R., Appanah, R., Jones, D. et al. DNA2 enables growth by restricting recombination-restarted replication. Nature (2025). https://doi.org/10.1038/s41586-025-09470-5

Image Credits: AI Generated